Sichuan Biokin Pharmaceutical News and Activities

Sichuan Biokin Pharmaceutical is one of the...

• CSI 300;
• Forbes Global 2000 (#1955);
• TOB Iconic 10,000.

Sichuan Biokin Pharmaceutical is a company listed under the stock ticker 688506 (CN).

Acquisition, funding and merger involving Sichuan Biokin Pharmaceutical.

• Sichuan Biokin Pharmaceutical has just announced a $387 Million fundraising (posted on January 2 2026).

View the org chart displaying its 11 main executives

Most searched biographies at Sichuan Biokin Pharmaceutical

• Yi Zhu, Chairman of the Board, Chief Scientific Officer and Genera...
• Shi Zhuo, Director
• Hai Zhu, Director

Create your alert
to follow the executive moves at Sichuan Biokin Pharmaceutical.

Sichuan Biokin Pharmaceutical has 1,913 competitors including Sanofi (France), Eli Lilly (United States (USA)) and Moderna (United States (USA)).

Popular M&A news in Pharmaceuticals

• Corden Pharma has announced the acquisition of AmbioPharm  (posted on June 5 2026).
• Laboratoire Servier has announced the acquisition of Edgewise Therapeutics  (posted on June 4 2026).
• Contraline has just announced a $93 Million fundraising (posted on June 3 2026).

Popular contacts in Pharmaceuticals

• Joaquin Duato - Chief Executive Officer and Chairman of the Board at Johnson & Johnson
• Robert Ford - Chief Executive Officer and Chairman of the Board at Abbott
• Jonathan Leff - Director at Larimar Therapeutics

Learn more about the Pharmaceuticals industry

Press releases by Sichuan Biokin Pharmaceutical

Social media about Sichuan Biokin Pharmaceutical

• Sichuan Biokin Pharmaceutical on Wikipedia, Google News & Yahoo Finance
• Sichuan Biokin Pharmaceutical on LinkedIn, X (Twitter) & YouTube